ERBB2 and neoplasm: Among tissue immunohistochemistry markers assessed for prognostic value, tumour vascular endothelial growth factor (VEGF) response to neoadjuvant therapy has been noted to predict for more aggressive disease biology, while tumour HER2/neu expression was not found to be prognostic (15, 16).Imaging response surrogates using 18F-fluorodeoxyglucose positron emission tomography, computed tomography (18F-FDG PET-CT) and dynamic contrast enhanced magnetic resonance imaging (DCE-MRI) have been evaluated as markers for response to neoadjuvant chemotherapy (17, 18).